HORMONAL-METABOLIC PATTERN OF POSTMENOPAUSAL FEMALES WITH NEW ONSET OF DIABETES MELLITUS TYPE 2: THE ROLE OF CANCER AND HEREDITARY PREDISPOSITION TO DIABETES

Cover Page

Abstract


85 females were studied, 35 females had new onset of diabetes (DM2) and in 50 women DM2 was associated with recently diagnosed cancer (C+DM2). Group C+DM2 was characterized by higher levels of body mass index, insulinemia, estradiolemia, interleukin 6 in serum, and glyoxalase I activity in mononuclears. At the same time  patients in C+DM2 group who had familial predisposition to DM2 were characterized by lower body mass index, body fat content, waist circumference, insulinemia, serum interleukin 6, viscosity of erythrocyte membranes and percent of comets in mononuclears in comparison with patients without familial predisposition to DM2. These trends were mostly opposite to the data of subgroups comparison (with or without relatives with DM2) in females with DM2 without cancer. The conclusion is made that the hereditary load with DM2 is differently realized in diabetics with higher or lower predisposition to cancer that deserves further study.

 


L. M. Berstein

N.N. Petrov Research Institute of Oncology, St. Petersburg, Russian Federation

Author for correspondence.
Email: levmb@endocrin.spb.ru

Russian Federation PhD, Professor, Head of Oncoendocrinology Laboratory, Research Institute of Oncology named after N.N. Petrov Address: 197758, St. Petersburg, Pesochnyi Village, Leningradskaya St., 68; tel.: (812) 596-86-54

D. A. Vasil’ev

N.N. Petrov Research Institute of Oncology, St. Petersburg, Russian Federation

Email: dvasilyev@hotmail.com

Russian Federation PhD, Senior Research Worker, Laboratory of Oncoendocrinology, Research Institute of Oncology named after N.N. Petrov Address: 197758, St. Petersburg, Pesochnyi Village, Leningradskaya St., 68; tel.: (812) 596-85-49

T. E. Poroshina

N.N. Petrov Research Institute of Oncology, St. Petersburg, Russian Federation

Email: levmb@endocrin.spb.ru

Russian Federation Physician of Clinical and Laboratory Diagnostics, Laboratory of Endocrinology, Research Institute of Oncology named after N.N. Petrov Address: 197758, St. Petersburg, Pesochnyi Village, Leningradskaya St., 68; tel.: (812) 596-85-49

M. P. Boyarkina

N.N. Petrov Research Institute of Oncology, St. Petersburg, Russian Federation

Email: bomari@list.ru

Russian Federation Endocrinologist, Laboratory of Endocrinology, Research Institute of Oncology named after N.N. Petrov Address: 197758, St. Petersburg, Pesochnyi Village, Leningradskaya St., 68; tel.: (812) 596-85-49

E. V. Tsyrlina

N.N. Petrov Research Institute of Oncology, St. Petersburg, Russian Federation

Email: evg.tsyrlina@gmail.com

Russian Federation PhD, Leading Research Worker, Laboratory of Endocrinology, Research Institute of Oncology named after N.N. Petrov Address: 197758, St. Petersburg, Pesochnyi Village, Leningradskaya St., 68; tel.: (812) 596-85-49

  1. Dedov I.I., Shestakova M.V. Sakharnyi diabet i arterial'naya gipertenziya [Diabetes and Hypertension]. Moscow, MIA, 2006. 340 p.
  2. Giovannucci E., Harlan D.M., Archer M.C., Bergenstal R.M., Gapstur S.M., Habel L.A., Pollak M., Regensteiner J.G., Yee D. Diabetes and cancer: a consensus report. Diabetes Care. 2010; 33 (7): 1674–1685.
  3. Liu X., Ji J., Sundquist K., Sundquist J., Hemminki K. The impact of type 2 diabetes mellitus on cancer-specific survival: a follow-up study in Sweden. Cancer. 2012; 118 (5): 1353–1361.
  4. Pappas Y., Wei I., Car J., Majeed A., Sheikh A. Computer-assisted versus oral-and-written family history taking for identifying people with elevated risk of type 2 diabetes mellitus. Cochr. Database Syst. Rev. 2011; 12: CD008489.
  5. Hemminki K., Li X., Sundquist J., Sundquist K. Risk of cancer following hospitalization for type 2 diabetes. Oncologist. 2010; 15 (6): 548–555.
  6. Bershtein L.M., Boyarkina M.P., Teslenko S.Yu., Vasil'ev D.A. Frequency of family diabetes in diabetic patients with cancer. Vopr. onkologii = Oncological issues. 2011; 57 (4): 443–447.
  7. Lindstrom J., Tuomilehto J. The diabetes risk score: a practical tool to predict type 2 diabetes risk. Diabetes Care. 2003; 26: 725–731.
  8. Goto A., Song Y., Chen B.H., Song Y., Aziz N., You N.C., Wellons M.F., Manson J.E., White D.L., Butch A.W., Liu S. Coffee and caffeine consumption in relation to sex hormone-binding globulin and risk of type 2 diabetes in postmenopausal women. Diabetes. 2011; 60 (1): 269–275.
  9. Dandona P., Thusu K., Cook S., Snyder B., Makowski J., Armstrong D., Nicotera T. Oxidative damage to DNA in diabetes mellitus. Lancet. 1996; 347 (8999): 444–445.
  10. Piconi L, Quagliaro L, Ceriello A. Oxidative stress in diabetes. Clin. Chem. Lab. Med. 2003; 41 (9): 1144–1149.
  11. Brauer P.M., Mc Keown-Eyssen G.E., Jazmaji V., Logan A.G., Andrews D.F., Jenkins D., Marcon N., Saibil F., Cohen L., Stern H., Baron D., Greenberg G., Diamandis E., Kakis G., Singer W., Steiner G. Familial aggregation of diabetes and hypertension in a case-control study of colorectal neoplasia. Am. J. Epidemiol. 2002; 156 (8): 702–713.
  12. Berstein LM, Boyarkina MP, Teslenko S.Y. Familial diabetes is associated with reduced risk of cancer in diabetic patients: a possible role for metformin. Medical Oncology. 2012; 29 (2):1308–1313.
  13. Calle E.E., Kaaks R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat. Rev. Cancer. 2004; 4 (8): 579–591.
  14. Ravishankaran P., Karunanithi R. Clinical significance of preoperative serum interleukin-6 and C-reactive protein level in breast cancer patients. World J. Surg. Oncol. 2011; 9: 18.
  15. Reztsova V.V., Kovalenko I.G., Bershtein L.M. Methyl glyoxal and glyoxalase in tumor growth and diabetes. Vopr. onkologii = Oncological issues. 2008; 54 (2): 142–147.
  16. Papazafiropoulou A., Sotiropoulos A., Skliros E., Kardara M., Kokolaki A., Apostolou O., Pappas S. Familial history of diabetes and clinical characteristics in Greek subjects with type 2 diabetes. BMC Endocrine Disorders. 2009; 9: 12.

Views

Abstract - 20

PDF (Russian) - 2

Cited-By


PlumX



Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.